Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study

Movement Disorders : Official Journal of the Movement Disorder Society
Karin Stiasny-KolsterRotigotine Sp 666 Study Group

Abstract

Efficacy and safety of the dopamine agonist rotigotine (RTG) was investigated in patients with moderate to severe idiopathic restless legs syndrome (RLS), including daytime symptoms. Three fixed doses of rotigotine (1.125 mg, 2.25 mg, and 4.5 mg) and placebo were applied by patches (size, 2.5 cm2 per 1.125 mg) in a double-blind, randomized, parallel-group, multicenter, 1-week, proof-of-principle trial. The primary efficacy measure was the total score on the International Restless Legs Syndrome Scale (IRLS). Additionally, the RLS-6 scale, the Clinical Global Impressions (CGI), and a sleep diary were used. Of 68 enrolled patients, 63 (mean age, 58+/-; 9 years; 64% women) were randomly assigned. RLS severity improved related to dose by 10.5 (1.125 mg RTG/die; P = 0.41), 12.3 (2.25 mg RTG/die; P = 0.18), and 15.7 points (4.5 mg RTG/die; P < 0.01) on the IRLS compared to placebo (8 points). According to the RLS-6 scales, daytime symptoms significantly improved with all rotigotine doses. The CGI items supported the favorable efficacy of the 4.5-mg dose. Skin tolerability of the patches and systemic side effects were similar between rotigotine and placebo. This pilot study suggests that continuous delivery of rotigotine by means of a ...Continue Reading

References

Sep 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·A S Walters
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J WinkelmannC Trenkwalder
Mar 23, 2002·Neurology·Cynthia L Comella
Jan 18, 2003·Sleep Medicine Reviews·Karin StiasnyClaudia Trenkwalder
May 23, 2003·The New England Journal of Medicine·Christopher J Earley
Jul 29, 2003·Expert Opinion on Investigational Drugs·Paul Tuite, Jennifer Riss
Aug 22, 2003·The New England Journal of Medicine·K Ray Chaudhuri
Nov 1, 2003·Sleep Medicine·Arthur S WaltersUNKNOWN International Restless Legs Syndrome Study Group
Apr 28, 2004·Neurology·C TrenkwalderUNKNOWN PEARLS Study Group

❮ Previous
Next ❯

Citations

May 16, 2009·Journal of Neurology·Claudia TrenkwalderJuliane Winkelmann
Dec 29, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Giovanni Merlino, Gian Luigi Gigli
Jul 10, 2007·Current Neurology and Neuroscience Reports·John C Morgan, Kapil D Sethi
Aug 28, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark J Buchfuhrer
Jun 10, 2010·Nature Reviews. Neurology·Claudia Trenkwalder, Walter Paulus
Nov 23, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J MontplaisirD Filipini
Nov 29, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M Steiger
Aug 19, 2011·BMC Medical Research Methodology·Milensu ShanyindeMark Weatherall
May 14, 2008·Annals of Family Medicine·William L BakerCraig I Coleman
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Giovanni MerlinoGian Luigi Gigli
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Ruth ByrneK Ray Chaudhuri
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Sabine Bunten, Svenja Happe
Jul 11, 2006·Drugs & Aging·Lorenzo PrianoAlessandro Mauro
May 20, 2008·CNS Drugs·Pankaj Satija, William G Ondo
Jan 1, 2006·The Libyan Journal of Medicine·Hani Benamer
Oct 3, 2006·Expert Review of Neurotherapeutics·John C Morgan, Kapil D Sethi
Mar 6, 2007·Expert Opinion on Drug Delivery·Y Naidu, K Ray Chaudhuri
Dec 1, 2005·Expert Opinion on Pharmacotherapy·Stephany Fulda, Thomas C Wetter
Feb 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Giovanni MerlinoGian Luigi Gigli
Feb 26, 2009·Expert Opinion on Pharmacotherapy·Olivier Rascol, Santiago Perez-Lloret
Mar 17, 2009·Expert Opinion on Pharmacotherapy·Luigi Ferini-Strambi
Aug 9, 2005·Expert Opinion on Emerging Drugs·Stephany Fulda, Thomas C Wetter
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Friederike Sixel-Döring, Claudia Trenkwalder
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Christopher Kenney, Joseph Jankovic
Oct 27, 2012·Neurologic Clinics·David B Rye, Lynn Marie Trotti
Jan 28, 2012·Sleep Medicine·Magdolna HornyakHanna Scholz
Sep 8, 2010·Sleep Medicine·Christopher J Earley, Michael H Silber
Feb 4, 2010·Parkinsonism & Related Disorders·Luigi Ferini-Strambi, Mauro Manconi
Nov 6, 2007·Seminars in Arthritis and Rheumatism·Wayne A Hening, Christine K Caivano
Oct 18, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderCristina Sampaio
Jun 7, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderJuergen Reess
May 29, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderMarco Zucconi
May 31, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Ralf KohnenMarco Zucconi
Sep 22, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L VignatelliUNKNOWN EFNS Task Force
Nov 30, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Wolfgang H OertelUNKNOWN Pramipexole RLS Study Group
May 23, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Wolfgang H OertelKarin Stiasny-Kolster
Jun 26, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Stephany Fulda, Thomas C Wetter
Feb 3, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderUNKNOWN CALDIR Study Group
Jan 3, 2007·The American Journal of Medicine·Wayne A Hening
Nov 24, 2007·Clinics in Geriatric Medicine·Kai Spiegelhalder, Magdolna Hornyak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.